Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

Table 1

Patient and treatment characteristics.

Features		Percent
Gender
Female	24	50.00
Male	24	50.00
Tumor histology
Liposarcoma	9	18.75
Synovial sarcoma	9	18.75
Unclassified sarcoma	9	18.75
Leiomyosarcoma	7	14.58
Osteosarcoma	5	10.42
Ewing’s sarcoma/primary	4	8.33
neuroectodermal tumor
Angiosarcoma	1	2.08
Desmoplastic small round cell tumor	1	2.08
Chondrosarcoma	1	2.08
Malignant phyllodes tumor	1	2.08
Rhabdomyosarcoma	1	2.08
Location of primary tumors
Upper limbs	4	8.33
Lower limbs	8	16.67
Nonextremities	36	75.00
High-grade sarcoma stage
Early disease with high risk of relapse	9	18.75
Advanced disease	39	81.25
Metastatic at diagnosis
Yes	14	29.17
No	34	70.83
LVEF assessments at both baseline
and end of study
Yes	38	79.17
No	10	20.83
Doxorubicin infusion cycles duration
72 hours	33	68.75
72/48 hours	15	31.25